Date: 26/06/2026

In the pharmaceutical industry, few inputs require as much attention as heparin. Used in anticoagulant therapies and highly complex procedures, it is directly linked to patient safety and treatment predictability.

This importance also makes its evaluation more demanding. From raw material sourcing to quality control, every stage can influence the potency, purity and consistency of the final product. Understanding how to evaluate heparin is therefore essential to reduce clinical risks, meet regulatory requirements and make more informed supplier selection decisions.

In this article, you will find:

How is heparin produced and controlled in the industry?

In the commercial heparin supply chain, porcine intestinal mucosa is the primary raw material used to obtain crude heparin. Because it is a biologically derived material, this intermediate must undergo controlled extraction, purification, standardization and laboratory evaluation processes before entering the pharmaceutical supply chain.

In simplified terms, the process involves:

● Raw material sourcing and selection: production begins with animal tissues suitable for industrial and pharmaceutical use, with controls over provenance and species of origin.
● Collection and stabilization: the intestinal mucosa is collected and preserved to reduce material degradation and microbial growth.
● Digestion and enzymatic extraction: at this stage, enzymes break down tissue components, typically from porcine intestinal mucosa, helping release heparin.
● Heparin isolation: the molecule is separated from other components present in the starting material by leveraging its chemical properties, such as its high negative charge.
● Purification: this stage aims to remove impurities such as proteins, nucleic acids, other glycosaminoglycans, microbiological contaminants and unwanted residues.
● Biological activity standardization: heparin must demonstrate anticoagulant activity within defined parameters. For sodium heparin, criteria include, among others, the anti-Xa to anti-IIa activity ratio and minimum potency per milligram.
● Microbiological and endotoxin control: because of its biological origin, microbiological controls are a core component of input safety. They help reduce risks associated with bacteria, fungi, endotoxins and other contaminants.
● Traceability and documentation: each batch must have documented history, identification records, production records, laboratory controls, storage conditions, certificate of analysis and information that enables distribution traceability in the event of a deviation or recall.

In Brazil, crude heparin is obtained from the intestinal mucosa of pigs approved under the Federal Inspection System. The process includes raw material selection, enzymatic digestion, isolation, purification, control of animal origin, dedicated transportation, prevention of cross-contamination, process monitoring, laboratory testing and batch-by-batch traceability.

What is the importance of heparin in anticoagulant treatments?

Heparin is a natural anticoagulant widely used in medicine to prevent and treat blood clot formation. In clinical practice, it is used in situations such as deep vein thrombosis, pulmonary embolism, cardiac surgery, extracorporeal circulation and hemodialysis.

Technically, heparin is a group of complex molecules (sulfated glycosaminoglycans) of biological origin, generally obtained from animal tissues, such as porcine intestinal mucosa in the case of commercial heparin. Its primary function is to reduce the blood’s ability to clot.

Pharmacological function

The anticoagulant effect of heparin begins when it binds to antithrombin, a naturally occurring protein that helps regulate blood coagulation. This interaction makes antithrombin significantly more effective at blocking factors involved in clot formation, particularly thrombin.

This action depends on a specific portion of the heparin molecule known as the pentasaccharide sequence. This sequence enables proper binding to antithrombin and induces a structural change that accelerates inhibition of the coagulation process.

Clinical applications

In clinical practice, heparin is used whenever it is necessary to prevent clot formation or stop existing clots from progressing. In surgical procedures, especially cardiac and arterial surgeries, it helps maintain controlled blood flow during higher-risk interventions. It is also used in extracorporeal circulation procedures, where blood temporarily passes through equipment outside the body.

In hemodialysis, heparin helps maintain the functionality of the extracorporeal circuit by preventing clot formation in the system’s tubing and filters. In cases of thrombosis, it may be used for both prevention and initial treatment of conditions such as deep vein thrombosis and pulmonary embolism.

What should be evaluated in heparin for pharmaceutical use?

Heparin is a highly critical input typically obtained from the intestinal mucosa of food-producing mammals. This requires a validated manufacturing process, including specification of the material’s origin. Production must also demonstrate the removal or inactivation of infectious and adventitious agents, as well as residual nucleic acids, proteins and heparinoids.

These characteristics make heparin a high-attention pharmaceutical input because its quality can directly influence the administered dose and the patient's response to treatment. In clinical practice, dosage is often adjusted based on coagulation testing. One of the parameters used is activated Partial Thromboplastin Time (aPTT), a test that measures blood clotting time. According to DailyMed, anticoagulation is generally considered adequate when clotting time is maintained between 1.5 and 2 times the normal value.

Control becomes even more important during highly complex procedures such as surgeries involving extracorporeal circulation. In these situations, patient response to heparin may vary significantly, requiring functional testing to confirm that anticoagulation levels are appropriate.

Purity and standardization are also critical during stages preceding the final drug product. In practice, crude heparin is not used directly in treatments. Before that, it undergoes processes such as purification, fractionation, potency control and impurity removal.

All these measures are necessary because heparin is a naturally heterogeneous molecule. Its chains can vary in size, degree of sulfation and sequence distribution. These differences may affect anticoagulant activity and make pharmaceutical standardization more challenging. For this reason, careful evaluation of the input is essential to ensure clinical safety and therapeutic predictability.

What to evaluate when selecting heparin as a pharmaceutical input

When selecting heparin for pharmaceutical use, the key consideration is the supplier’s ability to demonstrate quality, consistency and documentary control. The following criteria can help guide the selection process.

● GMP compliance: verify adherence to Good Manufacturing Practices applicable to active pharmaceutical ingredients, such as ICH Q7 and Brazil’s RDC 654/2022.
● Supply chain traceability: confirm animal origin, actual manufacturer, logistics chain, batch identification and traceability capabilities in the event of a deviation.
● Batch-to-batch consistency: evaluate potency history, impurity profile and anti-Xa/anti-IIa performance over time
● Purity and biological activity: confirm that the input meets requirements for potency, contaminants, impurities, microbiological quality and endotoxin levels.
● Technical documentation: request the CoA, laboratory records, analytical methods, release history, stability data, retest information and investigations related to out-of-specification results.
● Quality governance: assess audits, supplier qualification programs, change control procedures, data integrity practices and the ability to respond to inspections and quality deviations.

The impact of the supplier on safety and regulatory compliance

For heparin, suppliers directly influence areas that may present risk, including biological origin, manufacturing processes, impurity control, contamination prevention, batch consistency and regulatory documentation. Supplier selection should consider:

● Integrated supply chain: the greater the control over raw material sourcing and processing, the lower the likelihood of blind spots throughout the supply chain.
● Manufacturing controls: monitored processes, dedicated transportation, cross-contamination prevention and specialized laboratory testing help sustain input quality.
● Batch-to-batch consistency: consistent technical performance is essential to minimize variability in purification, potency and downstream pharmaceutical performance.
● Regulatory support: suppliers must provide robust technical documentation and respond effectively to audits, regulatory requirements and quality investigations.
● Quality governance: quality systems, change control, traceability and data integrity are essential to maintaining compliance.

Within the Human Health segment, MBRF Ingredients stands out for its rigorous processes, including monitoring, dedicated transportation, cross-contamination prevention and laboratory testing. In addition, MBRF Ingredients has a global presence and maintains a structured quality governance framework focused on Good Practices, technical controls and regulatory compliance.

Heparin: a critical input for safety and therapeutic efficacy

Heparin is used in clinical settings where the margin for error is extremely narrow, such as surgery, hemodialysis and the treatment of thromboembolic events. Its effect depends on interaction with antithrombin and inhibition of key coagulation factors. As a result, variations in potency, purity or molecular structure can alter therapeutic response and increase patient risk.

From an industrial perspective, heparin cannot be treated as a conventional raw material. Its biological origin, the molecule’s natural heterogeneity, the history of contamination events in the global supply chain, the need for standardized anticoagulant activity and strict traceability requirements make it a particularly sensitive pharmaceutical input.

For this reason, procurement decisions should consider potency, purity, batch-to-batch consistency, traceability, technical documentation and quality governance. Integrated supply chain models, such as that of MBRF Ingredients, can help reduce risks associated with heparin sourcing. Looking to improve the quality and safety of your processes? Contact our consultants.

Frequently asked questions about heparin

What is heparin and what is it used for?

Heparin is an anticoagulant used to prevent or treat the formation of blood clots. In clinical practice, it is used in situations requiring rapid coagulation control, such as surgery, hemodialysis, deep vein thrombosis and pulmonary embolism.

It is also used in extracorporeal circulation procedures, where blood temporarily passes through equipment outside the body, such as during certain cardiac surgeries and dialysis treatments.

How does heparin work in the body?

Heparin works by reducing the blood’s ability to form clots. Its effect occurs primarily through binding to antithrombin, a naturally occurring protein that helps regulate coagulation.

This mechanism does not directly dissolve existing clots. The primary role of heparin is to prevent the formation of new clots and stop existing clots from progressing. For this reason, its activity must be predictable, measurable and monitored through coagulation testing when used in clinical settings.

What are the risks associated with heparin use?

The primary risk associated with heparin therapy is bleeding, particularly when anticoagulant activity exceeds the intended level or when dosing is not appropriate for the patient profile. Key risks include:

● Hemorrhage, one of the most significant complications associated with heparin therapy.
● Variability in therapeutic response, as patients may respond differently to the medication.
● Out-of-specification anticoagulant activity resulting from potency variation between products or batches.
● Contamination or adulteration, a particularly sensitive risk because heparin is biologically derived.
● Microbiological or endotoxin contamination, which may compromise product safety.

How can quality be ensured in pharmaceutical inputs such as heparin?

Heparin quality depends on controls throughout the entire supply chain, including raw material sourcing, manufacturing processes, laboratory testing, technical documentation and traceability.

Within the commercial supply chain, the primary source of heparin is porcine intestinal mucosa, from which crude heparin is obtained. This material is not used directly in pharmaceutical products. Before reaching pharmaceutical-grade standards, it must undergo extraction, enzymatic digestion, isolation, purification, impurity removal, biological activity standardization, microbiological testing, endotoxin control and batch-by-batch traceability.

Together, these procedures ensure the quality and consistency of supplied batches.

What should be evaluated in heparin suppliers?

The selection of heparin suppliers should consider their ability to demonstrate quality, consistency, traceability and regulatory compliance.

Key evaluation criteria include:

● GMP compliance.
● Supply chain traceability.
● Batch-to-batch consistency.
● Purity and biological activity.
● Technical documentation.
● Quality governance.